

# News

## **Curidium Medica plc ("Curidium" or "the Company")**

### **CHANGE OF ADVISER**

**LONDON, UK, 23 January 2008, Curidium Medica plc, (LSE:CUR)**, the personalized medicine company focused on bringing the right drug to the right patient, announced today the appointment of JMFinn Capital Markets as nominated adviser and broker, with immediate effect.

Gosse B. Bruinsma, M.D., Executive Chairman, said "The appointment of JMFinn Capital Markets is a major step forward for Curidium and we are pleased to have them as our partners in further increasing awareness of Curidium Medica among investors."

### **Ends**

For further information please contact:

Gosse B. Bruinsma, M.D. +31 (0) 629 046 397  
Chairman, Curidium Medica plc

Rob Smith +44 (0) 20 7554 8793  
Finance Director, Curidium Medica plc

Charlie Cunningham +44 (0) 20 7600 1658  
JM Finn Capital Markets Ltd

Billy Clegg / Edward Westropp / Annie Evangeli + 44 (0)20 7831 3113  
Financial Dynamics

### **Notes to Editors**

#### **Curidium Medica plc (Curidium)**

Curidium is a personalized medicine company developing companion diagnostics and targeted medicines to treat patients more effectively.

Curidium's initial focus on diseases of the Central Nervous System has resulted in

the identification of a blood diagnostic test, PsychINDx™, which classifies patients with schizophrenia/bipolar disorder into four subgroups. PsychINDx™ may have the potential to improve the treatment of patients with schizophrenia/bipolar disorder.

Many chronic human diseases are heterogeneous with patient populations consisting of mixed subgroups. Through the use of its proprietary analysis tool, Homomatrix®, Curidium aims to reveal different patient subgroups characterized by distinct underlying disease mechanisms potentially leading to the identification of:

1. Diagnostics for better identification and treatment within heterogeneous disease populations.
2. Improved therapies identified through novel drug targets.
3. Personalized medicines using companion diagnostics and targeted treatments.

Curidium intends to continue to use this approach to improve patient treatments in a variety of therapeutic areas. Further information on Curidium can be found at the Company's website: [www.curidium.com](http://www.curidium.com).

Curidium Medica plc © 2002-2008. All rights reserved.

Studio 10, Tiger House, London WC1H 9BY, United Kingdom.

Email: [info@curidium.com](mailto:info@curidium.com) Tel.: +44 (0)20 7554 8790, Fax: +44 (0)20 7554 8791